

- Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA), a class of glucose-lowering agents used in the treatment of type 2 diabetes mellitus (T2DM).
- It is expected that exenatide administered once-weekly (QW) would be associated with greater adherence and compliance than daily dosing; therefore, it is valuable to estimate the relative efficacy and tolerability of exenatide QW compared to the existing GLP-1 RAs that have been developed.
- A network meta-analysis was conducted to examine the relative efficacy and tolerability (risk of nausea and treatment discontinuation) of exenatide QW versus other GLP-1 RAs among patients with inadequate glucose control following treatment on metformin monotherapy
- Results of this study indicate that exenatide QW has similar effectiveness and tolerability compared to other GLP-1 RAs, for the treatment of T2DM in adults with inadequate glycemic control on metformin alone.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by AstraZeneca LP. Editorial assistance was provided by ICON plc. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2016. Creative Commons Attribution Noncommercial License (CC BY-NC).